Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects

Background: Not all patients with acid-related disorders receiving proton pump inhibitor (PP) treatment get adequate gastric pH control. The genetic variation of receptors, metabolic enzymes, and transporters are known to cause failures of therapies. We have conducted a study to evaluate the influence of gastric H+/K+-ATPase, CYP2C19, and ABCB1 polymorphisms on the pharmacokinetic and pharmacodynamic profiles of dexlansoprazole injection in healthy Chinese subjects. Methods: A total of 51 subjects were enrolled for pharmacokinetic and pharmacodynamic study after a single intravenous administration of 20 or 30 mg dexlansoprazole. Plasma concentrations were determined using a chiral liquid chromatography-mass spectrometry method. The intragastric pH and baseline-adjusted intragastric pH parameters were introduced to evaluate the pharmacodynamic characters. Genotyping was performed by polymerase chain reaction. Results: The pharmacokinetic parameters were significantly influenced by CYP2C19 phenotypes, and gastric acid secretion inhibition were affected by both gastric H+/K+-ATPase and CYP2C19 polymorphisms. Gastric H+/K+-ATPase genotypes had greater effects than CYP2C19 genotypes on the suppression of gastric acid secretion. Conclusion: Gastric H+/K+-ATPase polymorphism may be one of the main reasons that cause insufficient gastric acid inhibition.

• Publication year

  2017

• Venue

  Frontiers in Pharmacology

• Publication date

  2017-09-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fphar.2017.00670PMID 29018343PMCID 5614982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enantioselective determination of (R)- and (S)-lansoprazole in human plasma by chiral liquid chromatography with mass spectrometry and its application to a stereoselective pharmacokinetic study.

  2015cited by this paper
• Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

  2015cited by this paper
• Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

  2015cited by this paper
• A correlative study of polymorphisms of CYP2C19 and MDR1 C3435T with the pharmacokinetic profiles of lansoprazole and its main metabolites following single oral administration in healthy adult Chinese subjects

  2014cited by this paper
• Bioequivalence of Two Lansoprazole Delayed Release Capsules 30 mg in Healthy Male Volunteers under Fasting, Fed and Fasting-applesauce conditions: A Partial Replicate Crossover Study Design to Estimate the Pharmacokinetics of Highly Variable Drugs

  2013cited by this paper
• Challenges in the management of acute peptic ulcer bleeding.

  2013cited by this paper
• H+/K+-ATPase inhibitors: a patent review

  2013cited by this paper
• Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects

  2012influential reference
• CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

  2012cited by this paper
• Influence of Cytochrome P450 2C19 on the pharmacokinetics of lansoprazole administered by single and successive intravenous infusion in healthy Chinese volunteers

  2012cited by this paper
• Conformational rearrangement of gastric H+,K+-ATPase induced by an acid suppressant

  2011cited by this paper
• Dexlansoprazole MR – A review

  2011cited by this paper
• Recent Progress in Research on Proton Pump Inhibitors

  2011cited by this paper
• The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects

  2010cited by this paper
• Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers

  2010cited by this paper
• Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers

  2010cited by this paper
• Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

  2009cited by this paper
• Proton pump inhibitors: actions and reactions.

  2009cited by this paper
• Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects

  2009cited by this paper
• Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy

  2009cited by this paper
• Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

  2009cited by this paper
• The Gastric H,K ATPase as a Drug Target: Past, Present, and Future

  2007influential reference
• Gastric H,K-ATPase as a Drug Target

  2006cited by this paper
• Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype

  2006cited by this paper
• Sequence analysis of the genes encoding for H+/K+‐ATPase in autoimmune gastritis

  2006cited by this paper
• Review article: intragastric and oesophageal pH monitoring in patients with gastro‐oesophageal reflux disease

  2006cited by this paper
• Review article: similarities and differences among delayed‐release proton‐pump inhibitor formulations

  2005cited by this paper
• Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.

  2004cited by this paper
• Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.

  2004cited by this paper
• Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.

  2004cited by this paper
• Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole

  2004cited by this paper
• Proton pump inhibitors: an update.

  2002cited by this paper
• Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer

  2001cited by this paper
• Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents*

  1997cited by this paper
• Determination of R(+)- and S(–)-Lansoprazole Using Chiral Stationary-Phase Liquid Chromatography and Their Enantioselective Pharmacokinetics in Humans

  1996cited by this paper

• Relationship between CYP2C19 genotypes and proton pump inhibitorsʹs pharmacokinetics and pharmacodynamics: review

  2024cites this paper
• Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics

  2024cites this paper
• A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps

  2023cites this paper
• Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways

  2021cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

  2020cites this paper
• Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults

  2019cites this paper
• Effects of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors.

  2019cites this paper